Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vimseltinib in Tenosynovial Giant Cell Tumor (MOTION)
NCT05059262Phase 3Active, not recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 13
01
Overview
A Phase 3 trial of vimseltinib in tenosynovial giant cell tumor (TGCT), sponsored by Deciphera Pharmaceuticals. Started Oct 2021; status: active, not recruiting.
02
Drugs
vimseltinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT05059262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059262.